Tharimmune Inc. (THAR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for THAR in the last 30 days. The most recent was published Feb 18, 2026.
Latest news
25 items- SECTharimmune Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Canton Strategic Holdings, Inc. (0001861657) (Filer)
- PRTharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyNew NASDAQ Ticker Symbol "CNTN" to Begin Trading February 18, 2026Company Positioned to Support Institutional Adoption of First Privacy-Enabled Public Blockchain Processing $9 Trillion in Monthly Transaction VolumeNEW YORK, Feb. 17, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) (the "Company") the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the launch of a corporate rebrand in alignment with its digital asset treasury strategy. Effective Wednesday, February 18, 2026, the Company will change its name to Canton Strategic Holdings, Inc. In connection with the name change, the commo
- INSIDERSEC Form 3 filed by new insider Radkowski Angela Dominy3 - Tharimmune, Inc. (0001861657) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sommers Jill E.3 - Tharimmune, Inc. (0001861657) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wiley William Thomas Jr.3 - Tharimmune, Inc. (0001861657) (Issuer)
- INSIDERSEC Form 3 filed by new insider Asbury Jacob3 - Tharimmune, Inc. (0001861657) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Tharimmune Inc.SCHEDULE 13G - Tharimmune, Inc. (0001861657) (Subject)
- SECTharimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tharimmune, Inc. (0001861657) (Filer)
- PRTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerLeadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh
- SECSEC Form SCHEDULE 13G filed by Tharimmune Inc.SCHEDULE 13G - Tharimmune, Inc. (0001861657) (Subject)
- SECSEC Form SCHEDULE 13G filed by Tharimmune Inc.SCHEDULE 13G - Tharimmune, Inc. (0001861657) (Subject)
- SECTharimmune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - Tharimmune, Inc. (0001861657) (Filer)
- PRTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsNew Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20
- SECSEC Form DEFA14A filed by Tharimmune Inc.DEFA14A - Tharimmune, Inc. (0001861657) (Filer)
- SECTharimmune Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Tharimmune, Inc. (0001861657) (Filer)
- SECTharimmune Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Tharimmune, Inc. (0001861657) (Filer)
- PRTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct OfferingNEW YORK, Jan. 22, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the closing of its previously announced underwritten registered direct offering which included the issuance of 1,800,000 shares of its common stock at a price of $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares of common stock at a price of $2.9199 per pre-funded warrant. The gross proceeds to the Company from the offering are approximately $55 million, before deducting underwriting discounts and commissions and other offering expenses pay
- SECTharimmune Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Tharimmune, Inc. (0001861657) (Filer)
- SECSEC Form 424B5 filed by Tharimmune Inc.424B5 - Tharimmune, Inc. (0001861657) (Filer)
- PRTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered OfferingNEW YORK, Jan. 20, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the pricing of a $55 million registered offering. Tharimmune, Inc. operates a differentiated digital asset treasury strategy by actively participating in the Canton Network – a privacy-enabled, secure blockchain hosting trillions in assets on chain. The offering is expected to close on or about January 21, 2026, subject to the satisfaction of customary closing conditions. The transaction includes the issuance of 1,800,000 shares of its common stock at a price of $2.
- SECSEC Form EFFECT filed by Tharimmune Inc.EFFECT - Tharimmune, Inc. (0001861657) (Filer)
- SECSEC Form DEF 14A filed by Tharimmune Inc.DEF 14A - Tharimmune, Inc. (0001861657) (Filer)
- SECSEC Form 8-K filed by Tharimmune Inc.8-K - Tharimmune, Inc. (0001861657) (Filer)
- SECSEC Form S-3 filed by Tharimmune Inc.S-3 - Tharimmune, Inc. (0001861657) (Filer)
- SECSEC Form PRER14A filed by Tharimmune Inc.PRER14A - Tharimmune, Inc. (0001861657) (Filer)
THAR FAQ
6 questionsWhat is the latest news on THAR?
Quantisnow has not tracked any new filings, ratings or press releases for THAR in the last 30 days. The most recent wire item was published on February 18, 2026.Where does THAR stock trade?
Tharimmune Inc. (THAR) is listed on NASDAQ.What sector and industry is THAR in?
Tharimmune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Tharimmune Inc. go public?
Tharimmune Inc. (THAR) completed its IPO in 2022.What companies are similar to THAR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare THAR side-by-side with any of them on Quantisnow.How can I track THAR on Quantisnow?
Quantisnow aggregates Tharimmune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow THAR to receive live email and push alerts on every new disclosure.